The Low/high bcs permeability class boundary: Physicochemical comparison of metoprolol and labetalol

Molecular Pharmaceutics

Volumn 11, Issue 5, 2014, Pages 1707-1714

  Zur, Moran ^a   Gasparini, Marisa ^a   Wolk, Omri ^a   Amidon, Gordon L ^b   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biopharmaceutics Classification System (BCS); biowaiver; intestinal permeability; labetalol; metoprolol; reference standard; solubility

Indexed keywords

LABETALOL; METOPROLOL TARTRATE; MULTIDRUG RESISTANCE PROTEIN; OCTANOL; METOPROLOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SMALL INTESTINE; SMALL INTESTINE ABSORPTION; STANDARD; ANIMAL; CHEMISTRY; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; MALE; PERMEABILITY; SOLUBILITY; WISTAR RAT;

ANIMALS; CHROMATOGRAPHY, LIQUID; INTESTINAL ABSORPTION; LABETALOL; MALE; METOPROLOL; PERMEABILITY; RATS; RATS, WISTAR; SOLUBILITY;

EID: 84899843284     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500152y     Document Type: Article

References (59)

1. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-420
2. Dahan, A.; Miller, J.; Amidon, G. Prediction of solubility and permeability class membership: Provisional BCS classification of the world's top oral drugs AAPS J. 2009, 11 (4) 740-746
3. Yu, L.; Amidon, G.; Polli, J.; Zhao, H.; Mehta, M.; Conner, D.; Shah, V.; Lesko, L.; Chen, M.-L.; Lee, V. L.; Hussain, A. Biopharmaceutics classification system: The scientific basis for biowaiver extensions Pharm. Res. 2002, 19 (7) 921-925
4. Dahan, A.; Lennernäs, H.; Amidon, G. L. The fraction dose absorbed, in humans, and high jejunal human permeability relationship Mol. Pharmaceutics 2012, 9 (6) 1847-1851
5. Dahan, A.; Miller, J. M.; Hilfinger, J. M.; Yamashita, S.; Yu, L. X.; Lennernäs, H.; Amidon, G. L. High-permeability criterion for BCS classification: Segmental/pH dependent Permeability considerations Mol. Pharmaceutics 2010, 7 (5) 1827-1834
6. Polli, J. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms AAPS J. 2008, 10 (2) 289-299
7. Chen, M.-L.; Amidon, G.; Benet, L.; Lennernas, H.; Yu, L. The BCS, BDDCS, and regulatory guidances Pharm. Res. 2011, 28 (7) 1774-1778
8. Zur, M.; Hanson, A. S.; Dahan, A. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation Eur. J. Pharm. Sci. 2014, 10.1016/j.ejps.2013.11.007
9. CDER/FDA. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutical classification system; Center for Drug Evaluation and Research: 2000.
10. Amidon, K. S.; Langguth, P.; Lennernas, H.; Yu, L.; Amidon, G. L. Bioequivalence of oral products and the biopharmaceutics classification system: Science, regulation, and public policy Clin. Pharmacol. Ther. 2011, 90 (3) 467-470
11. Kim, J.-S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J.; Amidon, G. L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests Mol. Pharmaceutics 2006, 3 (6) 686-694
12. Regardh, C. G.; Borg, K. O.; Johansson, R.; Johnsson, G.; Palmer, L. Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man J. Pharmacokinet. Biopharm. 1974, 2 (4) 347-64
13. Incecayir, T.; Tsume, Y.; Amidon, G. L. Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: Use as a reference standard for BCS classification Mol. Pharmaceutics 2013, 10 (3) 958-966
14. Thiel-Demby, V. E.; Humphreys, J. E.; St. John Williams, L. A.; Ellens, H. M.; Shah, N.; Ayrton, A. D.; Polli, J. W. Biopharmaceutics classification system: Validation and learnings of an in vitro permeability assay Mol. Pharmaceutics 2009, 6 (1) 11-18
15. Volpe, D. A.; Faustino, P. J.; Ciavarella, A. B.; Asafu-Adjaye, E. B.; Ellison, C. D.; Yu, L. X.; Hussain, A. S. Classification of drug permeability with a caco-2 cell monolayer assay Clin. Res. Regul. Aff. 2007, 24 (1) 39-47
16. Benet, L. Z.; Larregieu, C. A. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted Clin. Pharmacol. Ther. 2010, 88 (3) 405-407
17. Beig, A.; Miller, J. M.; Dahan, A. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: The effect of PEG-400 on carbamazepine absorption Eur. J. Pharm. Biopharm. 2012, 81 (2) 386-391
18. Beig, A.; Miller, J. M.; Dahan, A. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off Eur. J. Pharm. Biopharm. 2013, 85 (3, Part B) 1293-1299
19. Miller, J. M.; Beig, A.; Carr, R. A.; Spence, J. K.; Dahan, A. A win-win solution in oral delivery of lipophilic drugs: Supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability Mol. Pharmaceutics 2012, 9 (7) 2009-2016
20. Miller, J. M.; Beig, A.; Carr, R. A.; Webster, G. K.; Dahan, A. The solubility-permeability interplay when using cosolvents for solubilization: Revising the way we use solubility-enabling formulations Mol. Pharmaceutics 2012, 9 (3) 581-590
21. Beig, A.; Agbaria, R.; Dahan, A. Oral delivery of lipophilic drugs: The tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations PLoS One 2013, 8 (7) e68237
22. Fairstein, M.; Swissa, R.; Dahan, A. Regional-dependent intestinal permeability and BCS classification: Elucidation of pH-related complexity in rats using pseudoephedrine AAPS J. 2013, 15 (2) 589-597
23. Miller, J. M.; Dahan, A.; Gupta, D.; Varghese, S.; Amidon, G. L. Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs J. Controlled Release 2009, 137 (1) 31-37
24. Miller, J. M.; Dahan, A.; Gupta, D.; Varghese, S.; Amidon, G. L. Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir Mol. Pharmaceutics 2010, 7 (4) 1223-1234
25. Dahan, A.; Beig, A.; Ioffe-Dahan, V.; Agbaria, R.; Miller, J. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: Increased apparent solubility and drug flux through the intestinal membrane AAPS J. 2013, 15 (2) 347-353
26. Dahan, A.; Miller, J. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs AAPS J. 2012, 14 (2) 244-251
27. Miller, J. M.; Dahan, A. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: Model validation Int. J. Pharm. 2012, 430 (1-2) 388-391
28. Dahan, A.; Miller, J. M.; Hoffman, A.; Amidon, G. E.; Amidon, G. L. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: Mechanistic modeling and application to progesterone J. Pharm. Sci. 2010, 99 (6) 2739-2749
29. Miller, J. M.; Beig, A.; Krieg, B. J.; Carr, R. A.; Borchardt, T. B.; Amidon, G. E.; Amidon, G. L.; Dahan, A. The solubility-permeability interplay: Mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol. Pharmaceutics 2011, 8 (5) 1848-1856
30. Dahan, A.; Amidon, G. Grapefruit juice and its constituents augment colchicine intestinal absorption: Potential hazardous interaction and the role of P-glycoprotein Pharm. Res. 2009, 26 (4) 883-892
31. Dahan, A.; West, B. T.; Amidon, G. L. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat Eur. J. Pharm. Sci. 2009, 36 (2-3) 320-329
32. Dahan, A.; Amidon, G. L. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting Am. J. Physiol. 2009, 297 (2) G371-G377
33. Dahan, A.; Sabit, H.; Amidon, G. L. Multiple efflux pumps are involved in the transepithelial transport of colchicine: Combined effect of P-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine Drug Metab. Dispos. 2009, 37 (10) 2028-2036
34. Mudie, D. M.; Amidon, G. L.; Amidon, G. E. Physiological parameters for oral delivery and in vitro testing Mol. Pharmaceutics 2010, 7 (5) 1388-1405
35. Dahan, A.; Amidon, G. L. MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting Int. J. Pharm. 2010, 386 (1-2) 216-220
36. Dahan, A.; Mendelman, A.; Amsili, S.; Ezov, N.; Hoffman, A. The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: Comparison between anesthetized and freely moving conscious rat models Eur. J. Pharm. Sci. 2007, 32 (4-5) 367-374
37. Martínez, V.; Maguregui, M. I.; Jiménez, R. M.; Alonso, R. M. Determination of the pKa values of β-blockers by automated potentiometric titrations J. Pharm. Biomed. Anal. 2000, 23 (2-3) 459-468
38. Pagliara, A.; Carrupt, P.-A.; Caron, G.; Gaillard, P.; Testa, B. Lipophilicity profiles of ampholytes Chem. Rev. 1997, 97 (8) 3385-3400
39. Yang, Y.; Faustino, P. J.; Volpe, D. A.; Ellison, C. D.; Lyon, R. C.; Yu, L. X. Biopharmaceutics classification of selected β-blockers: Solubility and permeability class membership Mol. Pharmaceutics 2007, 4 (4) 608-614
40. Dahan, A.; Wolk, O.; Kim, Y. H.; Ramachandran, C.; Crippen, G. M.; Takagi, T.; Bermejo, M.; Amidon, G. L. Purely in silico BCS classification: Science based quality standards for the world's drugs Mol. Pharmaceutics 2013, 10 (11) 4378-4390
41. Kasim, N. A.; Whitehouse, M.; Ramachandran, C.; Bermejo, M.; Lennernäs, H.; Hussain, A. S.; Junginger, H. E.; Stavchansky, S. A.; Midha, K. K.; Shah, V. P.; Amidon, G. L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharmaceutics 2004, 1 (1) 85-96
42. Pham-The, H.; Garrigues, T.; Bermejo, M.; González-álvarez, I.; Monteagudo, M. C.; Cabrera-Pérez, M. á. Provisional classification and in silico study of biopharmaceutical system based on Caco-2 cell permeability and dose number Mol. Pharmaceutics 2013, 10 (6) 2445-2461
43. Takagi, T.; Ramachandran, C.; Bermejo, M.; Yamashita, S.; Yu, L. X.; Amidon, G. L. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharmaceutics 2006, 3 (6) 631-643
44. Burgot, G.; Serrand, P.; Burgot, J. L. Thermodynamics of partitioning in the n-octanol/water system of some β-blockers Int. J. Pharm. 1990, 63 (1) 73-76
45. Henchoz, Y.; Guillarme, D.; Martel, S.; Rudaz, S.; Veuthey, J.-L.; Carrupt, P.-A. Fast log P determination by ultra-high-pressure liquid chromatography coupled with UV and mass spectrometry detections Anal. Bioanal. Chem. 2009, 394 (7) 1919-1930
46. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45 (12) 2615-2623
47. Cao, X.; Gibbs, S.; Fang, L.; Miller, H.; Landowski, C.; Shin, H.-C.; Lennernas, H.; Zhong, Y.; Amidon, G.; Yu, L.; Sun, D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model Pharm. Res. 2006, 23 (8) 1675-1686
48. Lennernäs, H. Human jejunal effective permeability and its correlation with preclinical drug absorption models J. Pharm. Pharmacol. 1997, 49 (7) 627-638
49. Lennernäs, H. Human intestinal permeability J. Pharm. Sci. 1998, 87 (4) 403-410
50. Lennernäs, H. Animal data: The contributions of the Ussing chamber and perfusion systems to predicting human oral drug delivery in vivo Adv. Drug Delivery Rev. 2007, 59 (11) 1103-1120
51. Yazdanian, M.; Glynn, S.; Wright, J.; Hawi, A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds Pharm. Res. 1998, 15 (9) 1490-1494
52. Varma, M. V.; Gardner, I.; Steyn, S. J.; Nkansah, P.; Rotter, C. J.; Whitney-Pickett, C.; Zhang, H.; Di, L.; Cram, M.; Fenner, K. S.; El-Kattan, A. F. pH-dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery Mol. Pharmaceutics 2012, 9 (5) 1199-1212
53. Meier, J. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents Am. Heart J. 1982, 104, 364-73
54. Abushammala, I.; Garrigues, T. M.; Casabó, V. G.; Nácher, A.; Martín-Villodre, A. Labetalol absorption kinetics: Rat small intestine and colon studies J. Pharm. Sci. 2006, 95 (8) 1733-1741
55. Jobin, G.; Cortot, A.; Godbillon, J.; Duval, M.; Schoeller, J.; Hirtz, J.; Bernier, J. Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum Br. J. Clin. Pharmacol. 1985, 19 (Suppl. 2) 97S-105S
56. Dahan, A.; Amidon, G. L. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: The role of efflux transport in the oral absorption of BCS class III drugs Mol. Pharmaceutics 2009, 6 (1) 19-28
57. MacLean, C.; Moenning, U.; Reichel, A.; Fricker, G. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats Drug Metab. Dispos. 2008, 36 (7) 1249-1254
58. Mouly, S.; Paine, M. P-glycoprotein increases from proximal to distal regions of human small intestine Pharm. Res. 2003, 20 (10) 1595-9
59. Thorn, M.; Finnstrom, N.; Lundgren, S.; Rane, A.; Loof, L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract Br. J. Clin. Pharmacol. 2005, 60 (1) 54-60